Shire Eyes Lifitegrast For Growth But Still Gets Dry Reception
Executive Summary
The specialty pharma expressed confidence about the late-stage dry-eye drug lifitegrast at a Dec. 10 R&D day, but analysts remain wary about whether Shire can hit sales goals based on its current pipeline.